Tag Archive for: Investors

Sector updates in October

  Investment funds  Orbimed secured $3 billion across two new funds, OrbiMed Private Investments X and OrbiMed Asia Partners VI, to build leading healthcare companies   Forbion secured €2.3 billion across two new funds, Forbion Growth Opportunities Fund IV and Forbion Ventures Fund VIII, to invest in high potential biotechs  TCGX secured $600 million for its […]

Hansa Biopharma participating in Pareto Securities’ 17th Annual Healthcare Conference 2026

Lund, Sweden, 27 August. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, will be presenting at Pareto Securities’ 17th Annual Healthcare Conference 2026 in Stockholm, at 12:45-13:05 CEST, on Wednesday 2 September, as well as participating in a panel discussion later that day at 14:50-15:10 CEST. Read more…

Register today: Anglonordic Life Science Conference 2026

As one of the organisers, Optimum is proud to partner with Anglonordic year on year to curate an awesome agenda for this fantastic event. Exclusively for European investors and R&D companies…

Hot topic: JPM 2026 – Deal or no deal – and does it matter?

JPM 2026 was touted as the event that would usher in the best year in biotech in a long time.  But when it happened there was a distinct lack of mega-deals to shout about.  The elephant, you might say, was not in the room.  Does this bode ill for 2026? Or is news of such […]

© Optimum Strategic Communications.